Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

罗米普洛斯蒂姆 医学 血小板减少性紫癜 安慰剂 临床终点 内科学 血小板生成素 血小板生成素 随机对照试验 临床试验 胃肠病学 血小板 巨核细胞 遗传学 替代医学 干细胞 病理 造血 生物
作者
David J. Kuter,James B. Bussel,Roger M. Lyons,Vinod Pullarkat,Terry Gernsheimer,Francis M. Senecal,Louis M. Aledort,James N. George,Craig M. Kessler,Miguel Á. Sanz,Howard A. Liebman,Frank T. Slovick,J. Th. M. de Wolf,Emmanuelle Bourgeois,Troy H. Guthrie,Adrian C. Newland,Jeffrey S. Wasser,Solomon I. Hamburg,Carlos Grande,François Lefrère
出处
期刊:The Lancet [Elsevier BV]
卷期号:371 (9610): 395-403 被引量:844
标识
DOI:10.1016/s0140-6736(08)60203-2
摘要

Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet destruction and decreased platelet production. Short-term administration of the thrombopoiesis-stimulating protein, romiplostim, has been shown to increase platelet counts in most patients with chronic ITP. We assessed the long-term administration of romiplostim in splenectomised and non-splenectomised patients with ITP.In two parallel trials, 63 splenectomised and 62 non-splenectomised patients with ITP and a mean of three platelet counts 30x10(9)/L or less were randomly assigned 2:1 to subcutaneous injections of romiplostim (n=42 in splenectomised study and n=41 in non-splenectomised study) or placebo (n=21 in both studies) every week for 24 weeks. Doses of study drug were adjusted to maintain platelet counts of 50x10(9)/L to 200x10(9)/L. The primary objectives were to assess the efficacy of romiplostim as measured by a durable platelet response (platelet count > or =50x10(9)/L during 6 or more of the last 8 weeks of treatment) and treatment safety. Analysis was per protocol. These studies are registered with ClinicalTrials.gov, numbers NCT00102323 and NCT00102336.A durable platelet response was achieved by 16 of 42 splenectomised patients given romplostim versus none of 21 given placebo (difference in proportion of patients responding 38% [95% CI 23.4-52.8], p=0.0013), and by 25 of 41 non-splenectomised patients given romplostim versus one of 21 given placebo (56% [38.7-73.7], p<0.0001). The overall platelet response rate (either durable or transient platelet response) was noted in 88% (36/41) of non-splenectomised and 79% (33/42) of splenectomised patients given romiplostim compared with 14% (three of 21) of non-splenectomised and no splenectomised patients given placebo (p<0.0001). Patients given romiplostim achieved platelet counts of 50x10(9)/L or more on a mean of 13.8 (SE 0.9) weeks (mean 12.3 [1.2] weeks in splenectomised group vs 15.2 [1.2] weeks in non-splenectomised group) compared with 0.8 (0.4) weeks for those given placebo (0.2 [0.1] weeks vs 1.3 [0.8] weeks). 87% (20/23) of patients given romiplostim (12/12 splenectomised and eight of 11 non-splenectomised patients) reduced or discontinued concurrent therapy compared with 38% (six of 16) of those given placebo (one of six splenectomised and five of ten non-splenectomised patients). Adverse events were much the same in patients given romiplostim and placebo. No antibodies against romiplostim or thrombopoietin were detected.Romiplostim was well tolerated, and increased and maintained platelet counts in splenectomised and non-splenectomised patients with ITP. Many patients were able to reduce or discontinue other ITP medications. Stimulation of platelet production by romiplostim may provide a new therapeutic option for patients with ITP.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
田様应助风中的飞机采纳,获得10
1秒前
乖猫要努力应助落后翠柏采纳,获得10
4秒前
6秒前
澡雪发布了新的文献求助10
6秒前
7秒前
8秒前
9秒前
Qian完成签到,获得积分10
9秒前
onlyan发布了新的文献求助10
10秒前
wjx关闭了wjx文献求助
12秒前
victorchen发布了新的文献求助10
12秒前
12秒前
小景毕业发布了新的文献求助10
13秒前
Yorshka完成签到,获得积分10
14秒前
16秒前
巫马夜安完成签到,获得积分10
17秒前
可爱的函函应助123采纳,获得10
17秒前
17秒前
wjx关闭了wjx文献求助
18秒前
18秒前
Bystander完成签到 ,获得积分10
19秒前
shine发布了新的文献求助10
19秒前
NexusExplorer应助复杂语山采纳,获得10
19秒前
yxy发布了新的文献求助10
19秒前
22秒前
WD发布了新的文献求助10
22秒前
wjx关闭了wjx文献求助
22秒前
留白完成签到 ,获得积分10
22秒前
小景毕业完成签到,获得积分10
23秒前
bkagyin应助lemon采纳,获得10
23秒前
卢哲发布了新的文献求助10
23秒前
华仔应助泡泡糖与一世安采纳,获得30
23秒前
曾经曼梅完成签到,获得积分10
26秒前
科研通AI2S应助Kollia采纳,获得30
26秒前
乐乐应助onlyan采纳,获得10
27秒前
27秒前
wjx关闭了wjx文献求助
27秒前
最短的咒发布了新的文献求助10
28秒前
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975458
求助须知:如何正确求助?哪些是违规求助? 3519866
关于积分的说明 11199996
捐赠科研通 3256213
什么是DOI,文献DOI怎么找? 1798133
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305